A new therapy for certain adults with relapsed or refractory acute myeloid leukemia (AML), developed by Celgene Corp. and Agios Pharmaceuticals Inc., has won earlier-than-expected FDA approval following a priority review.
Mateon Therapeutics Inc. said that, so far, five of 21 people with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome have achieved complete remissions after being treated with its vascular disrupting agent, Oxi-4503, in combination with cytarabine during a phase Ib dose-escalation study.
Nantcell Inc., the Patrick Soon-Shiong-backed company built in part with funds from the blockbuster albumin-bound chemotherapy Abraxane (nab-paclitaxel), has exclusively licensed Cytrx Corp.'s aldoxorubicin, another albumin-bound therapy, to incorporate into the treatment of multiple tumor types in combination with other immuno-oncology and cell-based therapies.
An Alexion Pharmaceuticals Inc. decision to cut ties with Moderna Therapeutics Inc., Blueprint Medicines Corp. and Arbutus Biopharma Corp. led an eventful day of biopharma earnings reports, shaped by better-than-expected results at the rare disease specialist.
Strong sales of Biogen Inc.'s pricey spinal muscular atrophy drug, Spinraza (nusinersen), helped the company cruise past consensus estimates and hit record second-quarter sales on Tuesday.
Mitsubishi Tanabe Pharma Corp. is buying Israel-based Neuroderm Ltd., the developer of a belt-worn pump for the continuous delivery of liquid levodopa/carbidopa to treat severe Parkinson’s disease (PD), for $1.1 billion in cash, or $39 per share. The deal is expected to play a key role in helping the Japanese company reach its goal of earning ¥80 billion (US$719.5 million) in U.S. revenue by 2020, in part by expanding its U.S. neurology portfolio.
Mitsubishi Tanabe Pharma Corp. is buying Israel-based Neuroderm Ltd., the developer of a belt-worn pump for the continuous delivery of liquid levodopa/carbidopa to treat severe Parkinson's disease (PD), for $1.1 billion in cash, or $39 per share. The deal is expected to play a key role in helping the Japanese company reach its goal of earning ¥80 billion (US$719.5 million) in U.S. revenue by 2020, in part by expanding its U.S. neurology portfolio.
Mitsubishi Tanabe Pharma Corp. is buying Israel-based Neuroderm Ltd., the developer of a belt-worn pump for the continuous delivery of liquid levodopa/carbidopa to treat severe Parkinson's disease (PD), for $1.1 billion in cash, or $39 per share.
Trevi Therapeutics Inc. said a new $50.5 million series C financing led by New Enterprise Associates will help it advance the development of Nalbuphine ER, a twice-daily oral opioid in development for the treatment of two forms of severe itching. The round included new investors Lundbeckfonden Ventures, Omega Funds and Aperture Venture Partners, along with TPG Biotech, Trevi's largest investor and the leader of its $12.8 million series A in December 2012 and $25 million series B round in June 2014.
FDA staffers gathered to hear advice on better balancing support for new drug development with efforts to speed access to lower-cost generics got an earful from generics companies, payers and their representatives about how loopholes, citizen petitions and market gaming have left the balance of power tilted toward innovators.
